Salute e Benessere

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and…

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable debt securities, expected to support a roadmap rich in potential catalysts and a cash runway to the end of 2026Strong market performance of other IL-17 inhibitors in hidradenitis suppurativa (HS) and other inflammatory indications validating large market opportunity for sonelokimab...
Nasdaq GlobeNewswire
07/11/2024

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall…

DUBLIN, Nov. 7, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), the company's commercial products in psychiatry, and ALKS 2680, an investigational medicine in development as a once-daily treatment for narcolepsy and idiopathic hypersomnia, at two scientific conferences this fall. The two meetings—the 37th Annual Psych Congress (Psych Congress), which took place…
PR Newswire
07/11/2024

MGI Tech Partners with the Human Cell Atlas to Further Advance Worldwide Human…

Under this partnership, HCA members will enjoy more access to MGI's cost-effective and scalable single cell and spatial omics solutions. In addition, MGI will also provide support to members in experimental design, assay execution, and bioinformatic support when applying MGI's technologies to their research. Under this partnership, HCA members will enjoy more access to MGI's cost-effective and scalable single cell and spatial omics solutions. In addition, MGI will also provide support to...
PR Newswire
07/11/2024

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial in acute optic neuritis (AON) with topline readout anticipated in December 2024Leadership team bolstered with extensive experience in key areas as the Company advances its late-stage pipeline and prepares for commercial phaseCash, cash equivalents and short-term investments of $125.0 million as of September 30, 2024, provides cash runway into...
Nasdaq GlobeNewswire
07/11/2024

NAYO to Announce the Launch of Fully Automated Biobanking Solutions in Europe at…

Chandler Luo, Chief Executive Officer of NAYO, said, "This exhibition is a fantastic platform for showcasing NAYO's liquid handlers and powerful innovation technology to a global audience. We hope to engage in meaningful discussions on cooperation with partners and leading medical institutions worldwide. By leveraging the flexible-based-platform, we aim to maximize resource utilization, foster close collaborations with medical professionals globally." Chandler Luo, Chief Executive…
PR Newswire
07/11/2024

LG UNVEILS "PROFESSIONAL LAUNDRY" LINEUP FOR COMMERCIAL MARKET AT TEXCARE 2024

LG's comprehensive range of large-capacity commercial washers and dryers provides several outstanding options for customers to choose from. The new PROFESSIONAL LAUNDRY lineup features 20-, 25- and 30-kilogram washers, as well as 25- and 30-kilogram dryers, along with a 25- kilogram washer-dryer combo. These solutions are equipped with LG's advanced AI technology, which automatically adjusts water usage and washing/drying times based on load size, enabling a complete cycle in just 60 minutes.*…
PR Newswire
07/11/2024

Serres Receives €1.8 Million Research Grant from Business Finland

"The project supports the company's strategic renewal, positioning it as a leader in sustainable development by providing solutions for collecting hospital patient fluids and plastic waste. This highly ambitious research project combines various aspects within its work packages to achieve the desired results. Business Finland's funding allows for implementing a large-scale project that improves international business prospects", states Eija-Riitta Hämäläinen at Business Finland…
PR Newswire
07/11/2024

Enzymatica AB's Interim report Q3/2024: Focus on developing existing and new…

"The two highest priorities on the company's agenda are accelerated sales in existing markets and partner agreements for new markets. Accordingly, we are strengthening our sales organization and planning to revamp our marketing strategy as well. The MDR certification we received last spring allows us to make new and stronger health claims. Over the past few weeks, the new MDR-labeled packages have started to appear on pharmacy shelves in Sweden, and new campaigns will soon follow. "The…
PR Newswire
07/11/2024

Q3 update: Novonesis delivers strong Q3 results and now expects full-year…

Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance has led Novonesis to now expect full-year organic sales growth to be at the upper end of the 7-8% range, and the adjusted EBITDA margin is confirmed to be between 35.5-36.5%.COPENHAGEN, Denmark – November 7, 2024.Novonesis delivers 9% organic sales growth, in the first nine months...
Nasdaq GlobeNewswire
07/11/2024

Trading statement 9M 2024

Organic pro forma sales growth of 9%, including 11% in the third quarter. Full-year organic sales growth outlook now expected at the upper end of the 7-8% range and the adjusted EBITDA margin confirmed between 35.5-36.5%.Ester Baiget, President & CEO: “We continue to execute strongly across the business. Supportive, broad-based demand coupled with strong innovation and commercial focus drive higher market penetration. Novonesis' biosolutions are increasingly requested by customers to...
Nasdaq GlobeNewswire
07/11/2024

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

Nine-Month Key Financial HighlightsTotal revenues of €116.6 million, including product sales of €112.5 millionNet Profit of €24.7 million, including proceeds from the Priority Review Voucher (PRV) 1sale Operating profit of €34.2 million compared to an operating loss of €57.2 million in the first nine-months of 2023Cash position of €156.3 million Includes €61.2 million in gross proceeds from recent private placement 2 Lower cash burn expected in the second half of 2024 as...
Nasdaq GlobeNewswire
07/11/2024

Zealand Pharma Announces Financial Results for the First Nine Months of 2024

Company announcement – No. 49 / 2024 Zealand Pharma Announces Financial Results for the First Nine Months of 2024Continued strong progress across obesity pipeline with proprietary assets ready for Phase 2 backed by a solid financial position. Presented extremely encouraging weight loss and tolerability data with long-acting amylin analog petrelintide from MAD Part 2 (16-week trial) at ObesityWeek 2024Announced positive topline results with GLP-1R/GLP-2R dual agonist dapiglutide...
Nasdaq GlobeNewswire
07/11/2024

Approx. USD 4.0 M Invested in Product Development for NTDs - GHIT's First…

In order to overcome this situation, the GHIT Fund has decided to invest approximately JPY 280 million (USD 2.0 million1) in a project led by US-based non-profit organization Drugs & Diagnostics for Tropical Diseases (DDTD), in collaboration with Medical & Biological Laboratories, Co. Ltd. (MBL) in Japan, The Carter Center (TCC, USA), and Big Eye Diagnostics, Inc. (BEDx, USA), with active support from the Centers for Disease Control and Prevention (CDC), to develop a Rapid Diagnostic…
PR Newswire
07/11/2024

This World Prematurity Day, Pampers is empowering the 82%[1] of parents who feel…

Fortunately, with the right information and support from neonatal professionals, parents can build confidence and be empowered to become partners in their babies' day-to-day care with essential interactions that support bonding. This approach is known as Family Integrated Care (FiCare), an important advancement in neonatal care, which positively impacts infant development, and improve the mental health of parents. Fortunately, with the right information and support from neonatal…
PR Newswire
07/11/2024

Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma…

Key Takeaways from the Severe Asthma Pipeline Report Key Takeaways from the Severe Asthma Pipeline Report Request a sample and discover the recent advances in severe asthma treatment drugs @ Severe Asthma Pipeline Report The severe asthma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage severe asthma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an...
PR Newswire
06/11/2024

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 10/31/2024100,093,87388,569,210For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,[email protected] Patricia Sosa Navarro, Chief of Staff to the...
Nasdaq GlobeNewswire
06/11/2024

DBV Technologies Reports Third Quarter 2024 Financial Results

DBV Technologies Reports Third Quarter 2024 Financial ResultsDBV closes Q3 2024 with a cash balance of $46.4 million; cash runway into Q1 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J200), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2024. The quarterly and nine months financial statements were approved by the Board of Directors on November 6, 2024. Financial Highlights...
Nasdaq GlobeNewswire
06/11/2024

Nyxoah Reports Third Quarter Financial and Operating Results

REGULATED INFORMATIONNyxoah ReportsThird Quarter Financial and OperatingResults FDA approval on trackfor first quarter 2025 , U.S. commercial team build out in progress Companyfully funded with cash until mid 2026Mont-Saint-Guibert, Belgium –November 6 , 2024,10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq:...
Nasdaq GlobeNewswire
06/11/2024

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024…

ROCKVILLE, MD, November 6, 2024— MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance. Third Quarter and Recent HighlightsTotal revenue of $8.2 million in the third quarter of 2024, an increase of 2%...
Nasdaq GlobeNewswire
06/11/2024

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results

"Jazz once again delivered record revenues of more than $1.05 billion and a 14% year-over-year increase in revenue from our key growth drivers combined. We continue to see robust patient demand for Xywav with approximately 400 net patient additions in the third quarter, supported by physician and patient appreciation of a low-sodium treatment option. Strong sleep1 performance coupled with continued Epidiolex performance gives us confidence in maintaining our total revenue guidance of $4.0…
PR Newswire
06/11/2024

Interim Report Q3 2024: Further margin expansion and strong cash flow despite…

HighlightsThe Hearing division continued to gain significant market share leading to 10% organic revenue growth, while the divisional profit margin increased by 5.9 percentage points to 34.8%The Enterprise division was negatively impacted by sell-in pressure due to economic growth challenges in parts of Central Europe, while North America and Rest of World continued its stabilization. Overall, organic revenue growth ended at -7%, while sell-out growth was -3%. Despite the topline...
Nasdaq GlobeNewswire
06/11/2024

Update of financial guidance for 2024

GN has throughout the year increased its earnings power and cash flow generation, leading to an upgrade of the guidance on free cash flow excl. M&A to “DKK >1,100 million” and a confirmation of the EBITA margin guidance of “12 to 13%”. Following a somewhat softer market development than earlier anticipated for Enterprise and Gaming, GN adjusts its organic revenue growth guidance to “1% to 2%” Financial guidance for 2024Organic revenue growthReported EBITA marginFree cash...
Nasdaq GlobeNewswire
06/11/2024

With CAGR of 4.6 %, Eyelash Adhesives Market Size to Reach $2.97 Billion…

Overview of Report Findings Overview of Report Findings Download Sample Pages of Research analysis: https://www.theinsightpartners.com/sample/TIPRE00027378/ Market Segmentation Competitive Strategy and Development Global Headlines on Eyelash Adhesives Purchase Premium Copy of Global Eyelash AdhesivesMarketGrowth Report at:https://www.theinsightpartners.com/buy/TIPRE00027378/ Conclusion The global eyelash adhesives market is driven by several...
PR Newswire
06/11/2024

Genmab Announces Financial Results for the First Nine Months of 2024

November 6, 2024 Copenhagen, Denmark;Interim Report for the First Nine Months Ended September 30, 2024Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapyGenmab announced that it will assume sole responsibility for the continued development and potential...
Nasdaq GlobeNewswire
06/11/2024
Altri  Comunicati